Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy for RAS Wild-type Locally Advanced Rectal Cancer

NCT04923620 is registered in ClinicalTrials.gov with Shanghai Minimally Invasive Surgery Center as lead sponsor.

NCT NCT04923620
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04923620 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Neoadjuvant Cetuximab + Chemotherapy Combined With Short-course Radiotherapy for RAS Wild-type Locally Advanced Rectal Cancer
Lead sponsor
Shanghai Minimally Invasive Surgery Center
Phase
Observational
Overall status
Unknown status
Start date
October 20, 2021
Completion date
June 30, 2025
Enrollment
51 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cetuximab, neoadjuvant treatment, radiotherapy, rectal cancer